Provided by:
Viral Hepatitis Grand Rounds from the
Perelman School of Medicine at the
University of Pennsylvania
Academic Year 2014-2015
“Treatment challenges in HIV/HCV Coinfection”
October 8, 2014
12:00 PM (EDT) - 1:00 PM (EDT)
BRB 252 (Jane Glick Classroom)
Jay R. Kostman, MD
Clinical Professor of Medicine
Health System Clinician, University of Pennsylvania Health System
Attending Physician , Penn Presbyterian Medical Center
Associate Director, Viral Hepatitis Center Perelman School of Medicine
Philadelphia, Pennsylvania
Target Audience
This program has been designed for departmental/institutional faculty, fellows, residents, medical students, nurses,
nurse practitioners, physician assistants and allied health professionals in the medical specialties of infectious disease,
hepatology, gastroenterology, and internal medicine
Educational Objectives
After completing this activity, participants should be able to:
 Demonstrate increased understanding of the epidemiology of and risk factors for viral hepatitis.

Increase the rate of testing for viruses associated with hepatitis.

Demonstrate improved knowledge, competence and clinical practice in terms of the current standards and
guidelines for the management of patients with viral hepatitis.

Demonstrate an improved understanding of the treatment of viral hepatitis in patient co-infected with HIV or
other viral infections.
Accreditation
The Perelman School of Medicine at the University of Pennsylvania is accredited by the Accreditation Council for
Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation of Credit
The Perelman School of Medicine at the University of Pennsylvania designates this live activity for a maximum of 1 AMA
PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in
the activity.
Acknowledgement of Commercial Support*
Gilead Sciences Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc., Jansen Therapeutics, Division of Janssen
Products, LP, AbbVie Inc., Vertex Pharmaceuticals, Inc.
For more information, please contact
Richard Gordon
847-951-5318
rgorgdon@viraled.com
Check your CME online at www.penncmeonline.com
Disclosure of Relevant Financial Relationships and Unapproved Uses of Products
It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to
control the content of an educational activity to disclose to the learners all relevant financial relationships that they have
with any commercial interest that provides products or services that may be relevant to the content of this continuing
medical education activity. For this purpose we consider relationships of the person involved in the CME activity to
include financial relationships of a spouse or partner.
The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from
involvement in CME, but rather to ensure that Penn CME-certified activities promote quality and safety, are effective in
improving medical practice, are based on valid content, and are independent of control from commercial interests and
free of commercial bias. Peer review of all content was conducted for all faculty presentations whose disclosure
information provided to the Penn Office of CME was found to contain relationships that created a conflict of interest
relative to the topic of their presentation. In addition, all faculty were instructed to provide balanced, scientifically
rigorous and evidence-based presentations.
The staff in the Office of CME at the Perelman School of Medicine at the University of Pennsylvania, Mila Kostic,
Director of CME and the peer reviewer Zalman Agus, MD, Associate Dean for CME, have disclosed that they have
no relevant financial relationships with any commercial interests related to the content of this educational activity.
The following individuals have disclosed that they have no relevant financial relationships with any commercial interests
related to the content of this educational activity:
PLANNING COMMITTEE MEMBER NAME
BRIAN BOYLE
OLIVER FULTZ
MILA KOSTIC
MICHAEL SCHOEN, PHD
RICK GORDON
PRESENTER NAME
JAY R. KOSTMAN, MD
The following individuals have reported the listed relevant financial relationships with commercial interests related to
the content of this educational activity.
PLANNING COMMITTEE MEMBER NAME NAME OF COMMERCIAL INTEREST
DAVID KAPLAN, MD
BAYER PHARMACEUTICALS
IAN FRANK, MD
GILEAD, VIIV
JANSSEN
GLAXOSMITH KLINE, BAVARIAN NORDIC
K. RAJENDER REDDY, MD
JANSSEN, MERCK, GENENTECH-ROCHE, GILEAD, BMS, ABBVIE
JANSSEN, MERCK, GILEAD, BMS, ABBVIE
MARK SULKOWSKI, MD
ABBVIE, BMS, GILEAD, MERCK, JANSSEN, BIPI
ABBVIE, BMS, GILEAD, MERCK, JANSSEN, TOBIRA
GILEAD
RELATIONSHIP
RESEARCH SUPPORT
HONORARIUM
CONSULTANT
RESEARCH SUPPORT
HONORARIUM
RESEARCH SUPPORT
RESEARCH SUPPORT
SCIENTIFIC ADVISOR
DSMB
Relevant Financial Relationships: Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property
rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial
benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research),
consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is
received or expected
DISCLOSURE OF UNAPPROVED USES OF PRODUCTS
PRESENTER NAME
JAY R. KOSTMAN, MD
PRODUCT
SIMEPREVIR, SOFOSBUVIR
INVESTIGATIONAL AND/OR OFF-LABEL USE
IN COMBINATION WITHOUT INTERFERON IN HIV INFECTION